KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Inventory (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Change in Inventory for 6 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 123.73% year-over-year to -$3.4 million, compared with a TTM value of $10.6 million through Dec 2025, down 63.17%, and an annual FY2025 reading of $10.6 million, down 63.17% over the prior year.
  • Change in Inventory was -$3.4 million for Q4 2025 at Esperion Therapeutics, up from -$5.9 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $15.1 million in Q2 2025 and bottomed at -$6.4 million in Q2 2022.
  • Average Change in Inventory over 5 years is $4.4 million, with a median of $4.5 million recorded in 2023.
  • The sharpest move saw Change in Inventory crashed 274.32% in 2022, then surged 1739.94% in 2023.
  • Year by year, Change in Inventory stood at $422000.0 in 2021, then soared by 1240.28% to $5.7 million in 2022, then surged by 150.85% to $14.2 million in 2023, then rose by 1.42% to $14.4 million in 2024, then plummeted by 123.73% to -$3.4 million in 2025.
  • Business Quant data shows Change in Inventory for ESPR at -$3.4 million in Q4 2025, -$5.9 million in Q3 2025, and $15.1 million in Q2 2025.